Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1B Multi-Center, Non Randomized, Open-Label, Multiple Dose First-In-Human Study Of DS-6051b, An Oral ROS1 And NTRK Inhibitor, In Subjects With Metastatic and/or Unresectable Solid Tumors

Next Previous
Trial Profile

A Phase 1/1B Multi-Center, Non Randomized, Open-Label, Multiple Dose First-In-Human Study Of DS-6051b, An Oral ROS1 And NTRK Inhibitor, In Subjects With Metastatic and/or Unresectable Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Taletrectinib (Primary)
  • Indications Neuroendocrine tumours; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors AnHeart Therapeutics; Daiichi Sankyo Inc; Nuvation Bio

Most Recent Events

  • 31 Mar 2023 According to an AnHeart Therapeutics media release, the company presented updated results from a pooled analysis including patients from this, NCT04395677, and NCT02675491 trials, in an oral presentation at the European Lung Cancer Congress (ELCC) 2023.
  • 29 Oct 2020 Pooled analysis of two Phase 1 trials (NCT02279433 and NCT02675491) published in the AnHeart Therapeutics Media Release.
  • 29 Oct 2020 According to an AnHeart Therapeutics, the company announced publication of a pooled analysis of two Phase 1 trials (NCT02279433 and NCT02675491) in JTO Clinical and Research Reports, an official journal of the International Association for the Study of Lung Cancer. Dr. Sai-Hong Ignatius Ou, MD PhD was the lead and corresponding author of this publication.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top